Cargando…
Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
The cell surface ecto-enzyme CD38 is a promising target antigen for the treatment of hematological malignancies, as illustrated by the recent approval of daratumumab for the treatment of multiple myeloma. Our aim was to evaluate the potential of CD38-specific nanobodies as novel diagnostics for hema...
Autores principales: | Fumey, William, Koenigsdorf, Julia, Kunick, Valentin, Menzel, Stephan, Schütze, Kerstin, Unger, Mandy, Schriewer, Levin, Haag, Friedrich, Adam, Gerhard, Oberle, Anna, Binder, Mascha, Fliegert, Ralf, Guse, Andreas, Zhao, Yong Juan, Cheung Lee, Hon, Malavasi, Fabio, Goldbaum, Fernando, van Hegelsom, Rob, Stortelers, Catelijne, Bannas, Peter, Koch-Nolte, Friedrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662768/ https://www.ncbi.nlm.nih.gov/pubmed/29084989 http://dx.doi.org/10.1038/s41598-017-14112-6 |
Ejemplares similares
-
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018) -
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020) -
Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
por: Baum, Natalie, et al.
Publicado: (2021) -
Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
por: Baum, Natalie, et al.
Publicado: (2020) -
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)